We have expert spokespeople available to comment on everything from healthcare, research and policy issues in the current news agenda, to talking about myeloma and how it affects patients.
Our key spokespeople are below, but if you have a specific enquiry please do get in touch.
Eric Low OBE, Chief Executive
Key areas of interest: Eric is focused on accelerating research and development of the most promising new myeloma treatments including giving patients a voice in the decision-making process. He is an advocate of collaborative working between drug approval bodies, industry and medical research charities.
Eric established Myeloma UK in 1997 and played a key role in developing the Myeloma UK business model. The organisation has grown under Eric’s leadership, and today reaches thousands of people, in the UK and worldwide, who are affected by myeloma including the healthcare professionals dedicated to their care. He currently sits on the Board of the National Cancer Research Institute, and is part of the expert advisory group for the Accelerated Access Review.
Follow Eric on Twitter: @EricLowMUK
Judy Dewinter, Chairman and myeloma patient
Key areas of interest: Judy can provide insight into living with myeloma, and the importance of the discovery and development of new treatments for myeloma patients.
She has been Chairman of the Myeloma UK Board of Directors since 2006. As a passionate patient advocate, Judy speaks at national and international meetings and participates on various advisory boards. She also prioritises time to speak to patients and their families, knowing from personal experience the difficulty of living and coping with myeloma.
Follow Judy on Twitter: @JudyDewinter
Prof Graham Jackson, Director
Key areas of interest: Prof Jackson can offer insight into myeloma research and development, and comment on clinical trials in the UK, including the Myeloma UK Clinical Trial Network.
He joined the Myeloma UK Board of Directors in 2015. Prof Jackson is currently Professor of Haematology at Newcastle University and formerly Clinical Director of Haematology and Bone Marrow Transplantation at Newcastle Hospitals Trust. Prof Jackson is an active member of the National Myeloma Trials Committee and is currently Chief and Co-chief Investigator on a number of national clinical trials.
Kate Morgan, Policy and Public Affairs Manager
Key areas of interest: Kate works to ensure that myeloma patients in the UK are getting access to new and effective treatments. She can provide a perspective on regulation and pricing, access to treatment, as well as NHS reforms and commissioning.
Kate joined Myeloma UK in 2008 and has been instrumental in improving access to treatment for myeloma patients across the UK. She has a strong track record in delivering results which includes working with industry, Government and academia to secure and speed up access to treatment for patients. Kate is focused on ensuring that myeloma patients are receiving the right treatment, as and when they need it.
Monica Morris, Healthcare Professional Programme Manager
Key areas of interest: Monica leads our healthcare professional development programmes which are designed to enable better diagnosis, understanding of and response to myeloma patients’ treatment and care.
Monica has worked in haematology and myeloma for 26 years as both a Ward Sister and Clinical Nurse Specialist. She joined Myeloma UK in 2015 and leads on engagement with healthcare professionals which includes online educational resource Myeloma Academy.
Dr Simon Ridley, Director of Research
Key areas of interest: Simon has a background in biomedical research. He can provide expert opinion and insight into myeloma research including the discovery and development of new treatments, and the organisation’s health services research programme which is focused on better understanding the needs and experiences of people affected by myeloma.
Simon directs the research strategy at Myeloma UK. Working closely with Myeloma UK research partners and an independent Research Advisory Group comprising expert peer and patient input, he ensures that Myeloma UK addresses its long-term vision of finding a cure for myeloma, as well as current patient need. Simon has previously worked across the research charity, biotech and academic sectors, including at Alzheimer’s Research UK and the University of Cambridge. He has experience of working on research strategy and funding, including national and international partnership programmes with academia, government funders and industry.
Fiona Harvey, Director of External Affairs
Key areas of interest: Fiona leads the External Affairs Team at Myeloma UK which incorporates Communications, and Policy and Public Affairs. As part of the Executive Leadership Team she has oversight of Myeloma UK’s strategic priorities, and can comment on the organisation’s impact on the social, economic and political landscapes of myeloma treatment and care in the UK.
Fiona has worked in private sector communications and external affairs for 17 years. She previously worked for Thales as Director of Corporate Communications and has a significant track record in managing and delivering large scale campaigns. In this role, Fiona is responsible for developing the Myeloma UK brand, reputation and policy and public affairs strategy.
Follow Fiona on Twitter: @FionaHarvey77
Barbara Osborne, Director of Income Generation
Key areas of interest: Barbara has over 20 years of experience working for high profile charities, and is an Executive Committee Member of the Institute of Fundraising, Scotland. She can provide insight and comment on all areas of improving income generation from community fundraising and individual giving, to securing funding from trusts and foundations.
Barbara is part of the Executive Leadership Team at Myeloma UK and is responsible for the income generation strategy. She has a great deal of experience in delivering results driven fundraising and has previously worked for the British Heart Foundation (BHF) and the Children’s Hospice Association Scotland (CHAS).